

Economic Plan

This document identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Osteoarthritis

2 List of Modelling Questions

Clinical questions by scope area	<p>Analysis:</p> <p>What is the cost-effectiveness of oral analgesics for Osteoarthritis?</p> <p>In part answers clinical questions:</p> <ol style="list-style-type: none"> 1. What is the clinical and cost effectiveness of fixed-dose combinations of NSAIDs/cox 2 inhibitors + GPA for the management of osteoarthritis? 2. What is the clinical and cost effectiveness of etoricoxib 30mg for the management of osteoarthritis?
Population	<p>Adults with a clinical diagnosis of Osteoarthritis.</p> <p>Subgroups: older people/ high risk</p>
Interventions considered for inclusion	<p>Paracetamol</p> <p>NSAIDs (Diclofenac, Ibuprofen, Naproxen)</p> <p>COX-2 inhibitors (Celecoxib, Etoricoxib)</p> <p>COX-2 inhibitors+gastro-protective agent(GPA)</p> <p>NSAID+GPA</p> <p>NSAID+GPA (single pill) (Arthrotec, Axorid, Vimovo)</p>
Type of analysis	<p>Cost Utility Analysis.</p>